Trial Profile

Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 24 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pazopanib (Primary) ; Anastrozole; Letrozole
Indications Advanced breast cancer; Carcinoma
Focus Therapeutic Use

Most Recent Events

11 Dec 2020 Results of exploratory analysis assessing correlation between CTC levels with response to pazopanib presented at the 43rd Annual San Antonio Breast Cancer Symposium.
11 Jun 2020 Status changed from active, no longer recruiting to completed.
31 May 2020 Results assessing the clinical benefit (CB) of Pazopanib combined with nonsteroidal aromatase inhibitors (NSAIs) in patients with ABC resistant to NSAIs, were presented at the 56th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com